ArticleOncotarget2018
Integrated treatment using intraperitoneal radioimmunotherapy and positron emission tomography-guided surgery with
Article in Oncotarget, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 22 citations in OpenAlex.
- Initial demonstration of the Scratch-PET concept: an intraoperative PET with a hand-held detector.Radiological physics and technology · 2025Article
- Radioimmunotherapy for peritoneal carcinomatosis: Preclinical proof of concept to clinical translation.Cell reports. Medicine · 2025Review
- Preclinical evaluation ofBreast cancer research : BCR · 2025Article
- Zirconium 89 and Copper 64 for ImmunoPET: From Antibody Bioconjugation and Radiolabeling to Molecular Imaging.Pharmaceutics · 2024Review
- Preclinical Evaluation of aPharmaceutics · 2023Article
- TheranosticFrontiers in oncology · 2023Article
- Preclinical Safety Evaluation of Intraperitoneally Administered Cu-Conjugated Anti-EGFR Antibody NCAB001 for the Early Diagnosis of Pancreatic Cancer Using PET.Pharmaceutics · 2022Article
- In Vitro Tumor Cell-Binding Assay to Select High-Binding Antibody and Predict Therapy Response for PersonalizedInternational journal of molecular sciences · 2022Article
- Characterization and Stabilization of a NewPharmaceutics · 2021Article
- Evaluation ofPharmaceuticals (Basel, Switzerland) · 2021Article
- State of the Art in Radiolabeling of Antibodies with Common and Uncommon Radiometals for Preclinical and Clinical Immuno-PET.Bioconjugate chemistry · 2021Article
- Immuno-OpenPET: a novel approach for early diagnosis and image-guided surgery for small resectable pancreatic cancer.Scientific reports · 2020Article
- Article
- IntegratedOncotarget · 2018Article
Corrections and comments
- Commented on byIntegrated2018
Authors and funding
14 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Peritoneal dissemination is a common cause of death from gastrointestinal cancers and is difficult to treat using current therapeutic options, particularly late-phase disease. Here, we investigated the feasibility of integrated therapy using
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.